<?xml version="1.0" encoding="UTF-8"?>
<p>The primary end point was defined as reduction in the 
 <italic>JAK2</italic>-V617F allele burden of 50% or more at 24 weeks after registration. Secondary end points and response criteria are described in the 
 <italic>Online Supplementary Methods</italic>).
 <sup>
  <xref rid="b11-1040710" ref-type="bibr">11</xref>,
  <xref rid="b12-1040710" ref-type="bibr">12</xref>
 </sup>
</p>
